Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22725637 | 0.86 | KDM4E (0.50) | KDM4EALDH1A1AOC3HTR2AHRH1 | |
| SCHEMBL10125298 | 0.86 | KDM4E (0.50) | KDM4EALDH1A1AOC3HTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL14764229 | 0.84 | ALDH1A1 (0.48) | KDM4EALDH1A1AOC3HTR2AHRH1 | |
| SCHEMBL19397759 | 0.83 | KAT2B (0.47) | KAT2B | |
| SCHEMBL7586902 | 0.83 | HTR2A (0.52) | KDM4EALDH1A1AOC3HTR2AHRH1 | |
| SCHEMBL5173218 | 0.81 | DPP4 (0.50) | KDM4EALDH1A1AOC3SLC6A2SLC6A4 | |
| SCHEMBL19397703 | 0.80 | KAT2B (0.51) | KDM4EALDH1A1MAPTKAT2B | |
| SCHEMBL19397693 | 0.80 | KAT2B (0.51) | KDM4EALDH1A1MAPTKAT2B | |
| SCHEMBL6580098 | 0.78 | KDM4E (0.53) | KDM4EALDH1A1AOC3HTR2AHRH1 | |
| SCHEMBL19397756 | 0.78 | ESR1 (0.48) | KDM4EALDH1A1MAPTCYP2C9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | KDM4E 1061/4885ALDH1A1 2604/4885AOC3 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.